First-in-Human Clinical Trials in the United Kingdom: MHRA Guidance

First-in-human (FIH) studies mark a pivotal step in the clinical development of investigational medicinal products. These early-phase trials are conducted after preclinical evidence suggests acceptable safety, typically involving healthy volunteers or carefully selected patient groups. In the United Kingdom (UK), the Medicines and Healthcare products Regulatory Agency (MHRA) provides specific guidance for the design, approval, and oversight of FIH studies, emphasising participant safety, risk minimisation, and robust scientific justification. The UK’s established network of accredited Phase 1 clinical pharmacology units, combined with NHS and academic partnerships, has positioned the country as a leading destination for early clinical development programmes.

This guide examines MHRA requirements for FIH studies in the UK, covering regulatory submissions, safety monitoring, ethical considerations, and operational best practices for sponsors, CROs, and investigators.

Background and Regulatory Framework

Legal Basis for FIH Studies

FIH trials in the UK are regulated under the Medicines for Human Use (Clinical Trials) Regulations 2004, aligned with ICH E6(R2) GCP. Sponsors must obtain a Clinical Trial Authorisation (CTA) from MHRA and favourable opinion from a Research Ethics Committee (REC).

MHRA Guidance Documents

MHRA guidance on risk-adapted approaches, trial design, and safety escalation outlines the standards expected for FIH studies. This includes dose escalation strategies, sentinel dosing, and safety stopping rules.

Post-Brexit Context

Following Brexit, MHRA operates independently from the EU’s Clinical Trial Regulation but continues to align with ICH and EMA guidance to ensure international credibility of UK FIH data.

Core Insights into First-in-Human Trials

1. Clinical Trial Authorisation (CTA)

Sponsors must submit detailed CTAs including pharmacology, toxicology, and quality data. The Investigational Medicinal Product Dossier (IMPD) must justify the starting dose, escalation plan, and safety parameters.

2. Dose Escalation and Sentinel Dosing

MHRA recommends careful dose escalation protocols, beginning with single-dose sentinel cohorts before enrolling additional participants. Safety reviews between cohorts are mandatory.

3. Safety Monitoring

Continuous monitoring of vital signs, laboratory data, and adverse events is required. Independent Data Monitoring Committees (IDMCs) are often established for complex or high-risk studies.

4. Accredited Phase 1 Units

FIH studies must be conducted in MHRA-accredited clinical pharmacology units with immediate access to resuscitation and intensive care facilities.

5. Risk Mitigation Strategies

Protocol design must incorporate stopping rules, dose-limiting toxicity criteria, and clear risk mitigation pathways. This is especially important for biologics, gene therapies, and first-in-class drugs.

6. Ethical Oversight

RECs assess informed consent documents to ensure participants understand risks, including the limitations of preclinical data. Transparency and voluntariness are emphasised.

7. MHRA Inspections

MHRA inspects FIH sites for GCP compliance, focusing on dose escalation records, data integrity, pharmacovigilance procedures, and TMF documentation.

Best Practices for FIH Studies in the UK

• Develop robust IMPD packages with transparent toxicology-to-clinic justification.
• Implement adaptive dose escalation protocols with sentinel dosing.
• Ensure accredited Phase 1 units have full resuscitation capacity.
• Use independent safety monitoring committees for high-risk products.
• Maintain full TMF compliance with real-time documentation of safety reviews.

Scientific and Regulatory Evidence

• MHRA Guidance on Risk-Adapted Approaches
• Medicines for Human Use (Clinical Trials) Regulations 2004
• ICH E6(R2) – Good Clinical Practice
• ICH M3(R2) – Nonclinical Safety Studies
• EMA Guidance on FIH Dose Escalation Strategies

Special Considerations

• Oncology FIH Trials: Often conducted in patients rather than healthy volunteers due to toxicity concerns.
• Biologics and ATMPs: Require enhanced risk management, long-term follow-up, and complex safety monitoring.
• Pediatrics: Rarely included in FIH trials; subsequent trials may require bridging strategies.
• Decentralised Models: Limited applicability; most FIH studies require controlled clinical pharmacology units.

When Sponsors Should Seek Regulatory Advice

• When developing novel biologics, ATMPs, or high-risk first-in-class products.
• If dose escalation involves complex adaptive or Bayesian models.
• When integrating biomarker-driven endpoints into FIH protocols.
• For multinational FIH programmes requiring harmonisation with FDA and EMA.
• If REC raises ethical concerns regarding participant consent or risk disclosure.

FAQs

1. What approvals are needed for FIH trials in the UK?

A Clinical Trial Authorisation from MHRA and REC approval are required before trial initiation.

2. How are starting doses determined?

Based on preclinical toxicology, pharmacokinetics, and safety margins, documented in the IMPD.

3. What is sentinel dosing?

The practice of dosing a small number of participants initially, with safety review before dosing additional subjects.

4. Are Phase 1 units in the UK accredited?

Yes. MHRA accredits Phase 1 units conducting FIH trials, ensuring facilities meet safety standards.

5. How does MHRA monitor safety during FIH trials?

Through CTA submissions, safety reporting, and routine GCP inspections of trial sites and pharmacology units.

6. Can FIH trials be conducted in rare diseases?

Yes, when ethical, typically involving small patient cohorts with high unmet need rather than healthy volunteers.

7. What are common MHRA inspection findings in FIH trials?

Inadequate safety stopping rules, incomplete TMF documentation, and poor justification of starting doses.

Conclusion

First-in-human trials in the UK are tightly regulated, requiring robust protocols, MHRA authorisation, and REC approval. Accredited Phase 1 units, combined with strong pharmacovigilance practices, ensure participant safety while enabling early clinical development. Sponsors must adopt comprehensive risk mitigation, maintain GCP compliance, and engage proactively with regulators. With MHRA’s rigorous oversight and NHS-supported infrastructure, the UK continues to be a leading destination for FIH studies, contributing to global drug development pipelines.

The Role of Phase 1 Clinical Pharmacology Units in the UK

Phase 1 clinical pharmacology units in the United Kingdom (UK) are central to the country’s reputation as a global leader in early clinical development. These facilities specialize in first-in-human (FIH) and early-phase studies, testing investigational medicinal products (IMPs) in healthy volunteers or small patient groups to generate critical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) data. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees these units to ensure compliance with Good Clinical Practice (GCP), participant safety, and robust data integrity. The UK’s long-standing expertise, highly trained staff, and established infrastructure make it one of the preferred locations for global sponsors to conduct Phase 1 studies. Units are often integrated with academic hospitals, NHS facilities, and commercial CROs, forming a strong ecosystem for innovation.

This article examines the structure, regulation, and significance of Phase 1 clinical pharmacology units in the UK, highlighting safety standards, operational models, and inspection findings.

Background and Regulatory Framework

MHRA Oversight of Phase 1 Units

MHRA authorizes and inspects Phase 1 units under the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended). These inspections assess compliance with ICH E6(R2) GCP, safety reporting obligations, and trial master file (TMF) integrity.

First-in-Human Trial Requirements

Following high-profile FIH incidents, such as the TeGenero TGN1412 trial in 2006, MHRA strengthened requirements for Phase 1 units. This includes enhanced risk mitigation strategies, dose escalation rules, and emergency response preparedness.

Accreditation Scheme

The MHRA’s Phase 1 Accreditation Scheme designates units that meet higher safety and governance standards, providing additional assurance to sponsors and participants.

Core Clinical Trial Insights: UK Phase 1 Units

1. Safety Infrastructure

Units must maintain on-site medical staff, intensive care facilities, and emergency protocols. MHRA inspections often review staff training records, resuscitation equipment, and pharmacovigilance procedures.

2. Pharmacokinetic and Pharmacodynamic Studies

Phase 1 units conduct PK/PD studies to characterize drug absorption, metabolism, and excretion. Early biomarker studies are often integrated to support precision medicine development.

3. Healthy Volunteer Trials

Many Phase 1 trials are conducted in healthy volunteers, with recruitment managed through ethical safeguards, financial reimbursement oversight, and strict eligibility criteria.

4. Adaptive Early-Phase Designs

Adaptive and seamless designs are increasingly used in Phase 1 units, allowing for more efficient transition between dose cohorts or into Phase 2 studies when justified by safety data.

5. Data Integrity

Electronic systems, such as electronic data capture (EDC) and eSource platforms, are scrutinized by MHRA to ensure compliance with data integrity principles.

6. CRO and Academic Integration

Commercial CROs operate many Phase 1 units, often collaborating with NHS hospitals and universities to leverage infrastructure, patient populations, and specialized expertise.

7. Inspection Findings

Frequent MHRA findings in Phase 1 units include:

• Inadequate documentation of dose escalation decisions
• Weak emergency preparedness training
• Poor pharmacovigilance reporting practices
• Incomplete source data verification

Best Practices & Preventive Measures

• Seek MHRA Phase 1 Accreditation to demonstrate high safety standards.
• Develop robust SOPs for emergency response and dose escalation decisions.
• Ensure pharmacovigilance teams are trained in SUSAR and SAE reporting.
• Maintain inspection-ready TMFs and electronic systems validated to MHRA expectations.
• Engage in early scientific advice with MHRA for novel compounds or trial designs.

Scientific and Regulatory Evidence

• Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
• MHRA Phase 1 Accreditation Scheme Guidance
• ICH E6(R2) – Good Clinical Practice
• ICH M3(R2) – Nonclinical Safety Studies Guidance
• MHRA inspection reports and findings on Phase 1 units

Special Considerations

Phase 1 unit oversight varies depending on trial type:

• Oncology Phase 1 Trials: Require specialized monitoring for high-risk compounds.
• Pediatrics: Early-phase pediatric studies demand stricter ethical oversight and parental consent safeguards.
• Rare Diseases: Phase 1 units may integrate biomarker-driven studies to optimize small patient populations.
• Advanced Therapies: ATMPs require specialized handling, manufacturing, and safety monitoring infrastructure.

When Sponsors Should Seek Regulatory Advice

• When planning FIH studies with novel mechanisms of action or high-risk compounds.
• If integrating adaptive designs requiring early MHRA input.
• When trial designs involve rare diseases or pediatric populations.
• For advanced therapies requiring specialized site qualifications.
• If previous MHRA inspections identified compliance gaps in Phase 1 operations.

FAQs

1. What are Phase 1 clinical pharmacology units?

They are specialized facilities in the UK conducting early-phase trials, including FIH studies, under MHRA oversight.

2. What is the MHRA Phase 1 Accreditation Scheme?

A voluntary program recognizing units that meet higher safety and governance standards, offering reassurance to sponsors and participants.

3. What studies are conducted in Phase 1 units?

They include FIH trials, PK/PD studies, dose escalation studies, and sometimes small patient cohort evaluations.

4. What are common MHRA findings in Phase 1 inspections?

Weak pharmacovigilance reporting, poor emergency preparedness, and incomplete TMF documentation are common issues.

5. Do all Phase 1 trials involve healthy volunteers?

No. Some involve patients, especially in oncology or rare diseases where ethical justification supports early patient involvement.

6. How does MHRA ensure safety in FIH trials?

Through stringent IMPD requirements, enhanced safety monitoring, and inspection of Phase 1 units’ emergency preparedness.

7. How are CROs involved in UK Phase 1 trials?

Many Phase 1 units are run by CROs, often collaborating with NHS hospitals or universities for expertise and infrastructure support.

Conclusion

Phase 1 clinical pharmacology units are the foundation of early drug development in the UK, ensuring participant safety and scientific integrity in high-risk first-in-human studies. MHRA’s rigorous oversight, strengthened by the Phase 1 Accreditation Scheme, helps sponsors and investigators maintain world-class safety standards. By engaging early with regulators, maintaining strong SOPs, and preparing for inspections, sponsors can maximize the efficiency and reliability of early-phase clinical research in the UK.